Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals (Nasdaq:CRNX) furnished an 8-K covering its June 26 2025 R&D Day. Management unveiled new pre-clinical data on three assets—TSHR antagonist CRN12755 for Graves’ disease, SST3 agonist CRN10329 for ADPKD and drug-conjugate CRN09682 for SST2-positive tumors—and outlined the Phase 1/2 BRAVESST2 design enrolling up to 150 patients. Highlights include reductions in thyroid hormone, hyaluronic acid, IL-6 and cystic indices, plus dose-dependent anti-tumor activity. No financial results or guidance were provided; information is “furnished,” not “filed,” and forward-looking statements stress clinical, regulatory and financing risks.